金属硫蛋白(MT)在乳腺癌中的表达及预后价值探讨  

THE EXPRESSION OF MT AND ITS PROGNOSIS VALUE IN HUMAN BREAST CARCINOMA

作　　者：乌新林[1] 施琳[2] 李晓洁 马激扬[1] 

机构地区：[1]内蒙古医学院第一附属医院普外科,内蒙古呼和浩特010050 [2]内蒙古医学院病理教研室 [3]呼和浩特新城区卫生防保站

出　　处：《内蒙古医学院学报》2001年第1期1-4,共4页Acta Academiae Medicinae Neimongol

摘　　要：目的 :研究MT在乳腺癌中的表达 ,探讨其预后价值。方法 :采用免疫组化S -P法 ,检测 91例乳腺癌中MT的表达。结果 :a .MT表达与肿瘤大小、病理分型、组织学分级、局部复发、远处转移相关 (P <0 0 5 ) ,而与年龄、淋巴结转移无关 (P >0 0 5 )。b .单因素分析结果表明肿瘤大小、淋巴结状态、组织学分级 ,MT都有预后意义 ,其中肿瘤大小 ,淋巴结状态 ,MT具有独立预后价值。c.MT阳性表达者生存期短。结论 :MT有可能作为判断乳腺癌预后的生物学指标之一。Objective:To study the expression of metallothionein (MT) and determine their relationship with clinicopathological feature and prognosis in human breast carcinoma. Methods:Immurohistochemical technique, S-P method was used. Results:a. The expression of MT was associated with tumour size, pathological type, histological grade, local recurrence, distant metastasis(P<0 05), there was no relation between the expression of MT and ages, lymphnode metastasis(P>0 05). b.The result of logistical regression analysis showed that tumor size, lymphnode status, MT independent prognostic factors. c.Patients with positive MT lived shorter than those of negative. Conclusion:The findings suggested that the expression of MT may be a useful marker for predicting the prognosis of breast carcinoma.

关 键 词：乳腺癌 金属硫蛋白 免疫组化 预后 表达 

分 类 号：R737.907[医药卫生—肿瘤]